- Home
- SCZM vs ALVO Comparison
SCZM vs ALVO Comparison
Compare SCZM & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCZM | ALVO |
|---|---|---|
| Founded | N/A | 2013 |
| Country | Canada | Luxembourg |
| Employees | N/A | 1460 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 998.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCZM | ALVO |
|---|---|---|
| Price | $9.43 | $3.59 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $8.00 |
| AVG Volume (30 Days) | ★ 422.9K | 322.9K |
| Earning Date | 05-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.38 | $13.28 |
| Revenue Next Year | N/A | $18.63 |
| P/E Ratio | ★ $14.27 | $18.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.90 | $3.03 |
| 52 Week High | $17.65 | $11.85 |
Technical Indicators
Market Signals| Indicator | SCZM | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 52.80 |
| Support Level | $8.92 | $3.03 |
| Resistance Level | $9.88 | $3.93 |
| Average True Range (ATR) | 0.52 | 0.19 |
| MACD | 0.16 | 0.01 |
| Stochastic Oscillator | 87.45 | 74.30 |
Price Performance
Historical ComparisonAbout SCZM Santacruz Silver Mining Ltd. Common Shares
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapan, and Corporate and Other activities. Key revenue is generated from Zimapan.
About ALVO Alvotech
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.